This observation appears consistent with what has been recently reported in a pooled-analysis of individual data from four prospective trials, where HER2-low-positive patients experienced significantly lower pCR than those with HER2-0 breast cancer in the overall cohort and in HR-positive subgroup6. Here, ERBB2 is linked to breast carcinoma.